| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/12/2006 | 15:22 | PR Newswire (US) | Abbott Acquires a Majority of Shares of Kos Pharmaceuticals, Inc. | NASDAQ:KOSP | Kos Pharmaceuticals |
| 04/12/2006 | 21:36 | PR Newswire (US) | Abbott's Acquisition of Kos Pharmaceuticals, Inc. Clears Antitrust Review | NASDAQ:KOSP | Kos Pharmaceuticals |
| 14/11/2006 | 19:45 | PR Newswire (US) | Abbott Laboratories Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals, Inc. | NASDAQ:KOSP | Kos Pharmaceuticals |
| 09/11/2006 | 13:00 | Business Wire | Kos Reports a 17% Increase in Revenue, Earnings Per Share of $0.71, and Solid Cash Flow from Operations | NASDAQ:KOSP | Kos Pharmaceuticals |
| 07/11/2006 | 17:21 | PR Newswire (US) | Holland & Knight Leads Kos Pharmaceuticals, Inc. Buyout by Abbott Laboratories for $3.7 Billion | NASDAQ:KOSP | Kos Pharmaceuticals |
| 06/11/2006 | 13:50 | PR Newswire (US) | Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals | NASDAQ:KOSP | Kos Pharmaceuticals |
| 03/11/2006 | 15:31 | Business Wire | Kos to Report Third Quarter Results on November 9, 2006 Conference Call at 8:30 A.M. ET | NASDAQ:KOSP | Kos Pharmaceuticals |
| 21/09/2006 | 22:41 | Business Wire | Kos Announces Positive Overall Results for Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema | NASDAQ:KOSP | Kos Pharmaceuticals |
| 19/09/2006 | 13:00 | Business Wire | Kos to Present at the UBS Global Life Sciences Conference | NASDAQ:KOSP | Kos Pharmaceuticals |
| 18/09/2006 | 16:05 | Business Wire | Kos Pharmaceuticals Announces Compliance with NASDAQ Continued Listing Requirements | NASDAQ:KOSP | Kos Pharmaceuticals |
| 06/09/2006 | 14:30 | PR Newswire (US) | SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe | NASDAQ:KOSP | Kos Pharmaceuticals |
| 16/08/2006 | 22:15 | Business Wire | Kos Announces Notice from Nasdaq Regarding Potential Delisting | NASDAQ:KOSP | Kos Pharmaceuticals |
| 09/08/2006 | 18:42 | PR Newswire (US) | Arisaph Pharmaceuticals Announces Second Closing of $8 Million Equity Investment | NASDAQ:KOSP | Kos Pharmaceuticals |
| 08/08/2006 | 13:00 | Business Wire | Kos Reports 25% Increase in Revenue, Solid Financial Results and Progress in Research and Development | NASDAQ:KOSP | Kos Pharmaceuticals |
| 27/07/2006 | 16:26 | Business Wire | Kos to Report Second Quarter Results on August 8, 2006 Conference Call at 8:30 a.m. ET | NASDAQ:KOSP | Kos Pharmaceuticals |
| 25/07/2006 | 16:39 | Business Wire | Kos Reports Summary Results from Clinical Study on Benefits of Combining Aspirin with Optimized Niaspan(R) CF | NASDAQ:KOSP | Kos Pharmaceuticals |
| 12/07/2006 | 16:18 | Business Wire | Kos Submits Supplemental New Drug Application To FDA For New Niaspan(R) CF Range of Products | NASDAQ:KOSP | Kos Pharmaceuticals |
| 20/06/2006 | 08:00 | Business Wire | Niaspan(R) Combined with Low/Moderate Dosed Statin Achieves Better Total Lipid Control vs. Higher Dose Statin Monotherapy or Zo | NASDAQ:KOSP | Kos Pharmaceuticals |
| 07/06/2006 | 15:42 | Business Wire | Kos Announces Completion of Patient Randomization for Jerini's Phase III Clinical Trials of Icatibant for the Subcutaneous Trea | NASDAQ:KOSP | Kos Pharmaceuticals |
| 09/05/2006 | 13:00 | Business Wire | Kos Reports Continued Double Digit Increase in Revenue, Financial Results in Line with Guidance and Authorization for up to 7 M | NASDAQ:KOSP | Kos Pharmaceuticals |
| 08/05/2006 | 14:00 | PR Newswire (US) | SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM) | NASDAQ:KOSP | |
| 08/05/2006 | 09:00 | PR Newswire (US) | SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States | NASDAQ:KOSP | Kos Pharmaceuticals |
| 05/05/2006 | 16:51 | Business Wire | CORRECTING and REPLACING Kos Announces Presentation at the Bank of America 2006 Healthcare Conference | NASDAQ:KOSP | Kos Pharmaceuticals |
| 05/05/2006 | 14:30 | Business Wire | Kos Announces Presentation at the Bank of America 2006 Healthcare Conference | NASDAQ:KOSP | Kos Pharmaceuticals |
| 25/04/2006 | 19:09 | Business Wire | Kos Announces Presentation at the Deutsche Bank 2006 Healthcare Conference | NASDAQ:KOSP | Kos Pharmaceuticals |
| 24/04/2006 | 23:06 | Business Wire | Kos Pharmaceuticals to Report First Quarter Results on May 9, 2006 Conference Call at 8:30 A.M. ET | NASDAQ:KOSP | Kos Pharmaceuticals |
| 19/04/2006 | 16:25 | Business Wire | Kos Announces Annual Shareholders Meeting April 27, 2006 | NASDAQ:KOSP | Kos Pharmaceuticals |
| 12/04/2006 | 20:51 | Business Wire | Centers for Medicare and Medicaid Services (CMS) Advises Plans Niaspan(R) is Now a Part D Eligible Drug; Confirms Niaspan as an | NASDAQ:KOSP | Kos Pharmaceuticals |
| 01/03/2006 | 14:36 | Business Wire | Kos Announces Presentation at the Lehman Brothers Ninth Annual Global Healthcare Conference | NASDAQ:KOSP | Kos Pharmaceuticals |
| 28/02/2006 | 14:52 | Business Wire | Kos Announces Presentation at the SG Cowen 26th Annual Health Care Conference | NASDAQ:KOSP | Kos Pharmaceuticals |